Sun Pharma Sets July 7, 2026 as Record Date for ₹5 Final Dividend; AGM on July 31
Sun Pharma's 34th AGM is on July 31, 2026. The record date for a ₹5 final dividend for FY25-26 is July 7, 2026. Dividend payment is expected by August 7, 2026. Shareholders must update contact details by July 7, 2026, for TDS purposes.
The declaration of a final dividend and the setting of a record date are material events for shareholders, directly impacting their returns. The AGM is also a significant corporate governance event.
The announcement pertains to routine corporate actions like the AGM and dividend declaration, which are standard procedures and do not indicate a significant positive or negative shift in the company's performance or outlook.
Sun Pharmaceutical Industries Limited has announced that the 34th Annual General Meeting (AGM) is scheduled for Friday, 31 July 2026, at 4:00 p.m. (IST) and will be conducted through Video Conferencing (VC).
The Company has fixed Tuesday, 07 July 2026, as the Record Date for determining shareholders' entitlement to the final dividend of ₹5 per equity share for the financial year 2025-26. This dividend, if approved by shareholders at the AGM, is expected to be paid on or before Friday, 07 August 2026.
Shareholders are advised to ensure their contact details are updated with their Depository Participants or the Company’s Registrar and Transfer Agent to receive the AGM Notice, Annual Report, and dividend credit. Dividend payments are subject to applicable tax deductions at source. Shareholders can find TDS guidance and document submission processes on the company's website, with a deadline of Tuesday, 07 July 2026, for submitting requisite documents to ensure the correct TDS rate is applied.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.